ClinicalTrials.gg
CompletedNCT02736955Updated Dec 19, 2018Results posted

Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

A Phase 3 interventional study of Valbenazine in Tardive Dyskinesia, sponsored by Neurocrine Biosciences. Completed at 27 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-12-19.

Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
161
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.

Enrollment
4th of 14
161 · median 101
Started
2016
the only one that year
Phase 3
3 of 14
none open now
Registered
7th of 14
by date
Lead sponsor
11 of 14
Neurocrine Biosciences

Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 3, and was the 7th registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About valbenazine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing valbenazine in Tardive Dyskinesia, or all of them as a file.
02

Study summary

This Phase 3b, rollover study will provide participants who completed a Phase 3 valbenazine (NBI-98854) study open-label access to valbenazine (fixed doses administered once daily) for the treatment of adults with TD until valbenazine is anticipated to be available commercially or they complete 72 weeks of treatment. This study will allow enrollment of up to 150 medically stable male and female participants with TD who previously participated in and completed the NBI-98854-1304 (Kinect 3) or NBI-98854-1402 (Kinect 4) Phase 3 study.

Read the detailed description

This study was terminated after 60 weeks due to the commercial availability of valbenazine.

03

Conditions studied

  • Tardive Dyskinesia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have participated in and completed the NBI-98854-1304 (Kinect 3) or NBI-98854-1402 (Kinect 4) Phase 3 study.
  • Participants of must agree to use hormonal or two forms of nonhormonal (dual contraception) consistently throughout the study and until 30 days after the last dose of valbenazine.
  • If using maintenance medication(s) for schizophrenia or schizoaffective disorder, mood disorder, or other conditions, be on stable doses.
  • Be in general good health.
  • Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Have an active, unstable medical condition within 1 month prior to screening.
  • Have a known history of substance dependence, substance (drug) or alcohol abuse.
  • Have a significant risk of suicidal or violent behavior.
  • Have a known history of neuroleptic malignant syndrome.
  • Have a known history of long syndrome or cardiac arrhythmia.
  • Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed).
  • Have received an drug within 30 days before screening or plan to use an investigational drug (other than valbenazine) during the study.
  • Have a blood loss ≥550 mL or donated blood within 30 days prior to Baseline.
  • Have an allergy, , or intolerance to tetrabenazine.
  • Are currently pregnant or breastfeeding.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    Valbenazine

    Fixed dose of valbenazine administered once daily for up to 72 weeks

    Drug: Valbenazine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Monitored for Long-term Safety of Valbenazine

    Incidence of adverse events and monitoring of vital signs, clinical laboratory values, and electrocardiograms. All AEs were coded into preferred terms according to MedDRA (Medical Dictionary for Regulatory Activities) and classified by system organ class (SOC). Summaries of the incidence of all treatment-emergent AEs, treatment-related AEs, SAEs, and AEs leading to study drug discontinuation were prepared.

    Time frame: 60 weeks

Secondary outcomes

  1. Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale

    Clinician's perspective of the participant's overall severity of TD symptoms. The CGI-TD-Severity is based on a 7-point scale (range: 1= "Normal, not at all ill" to 7= "Among the most extremely ill patient"). A clinical response was defined as a CGI-TD-S score equal to "1" or "2."

    Time frame: Baseline and Weeks 12, 24, 36, 48, and 60

  2. Number of Participants With Clinical Response as Assessed by the Patient Satisfaction Questionnaire (PSQ)

    Participant's perspective of his/her satisfaction with valbenazine treatment. The PSQ is based on a 5-point scale (range: 1=very satisfied to 5=very dissatisfied). A clinical response was defined as a PSQ score equal to "1" or "2."

    Time frame: Baseline and Weeks 12, 24, 36, 48, and 60

07

Results

Posted Dec 19, 2018

Participant flow

Participant flow — Overall Study
MilestoneValbenazine 40 mgValbenazine 80 mgValbenazine 40/80 mg
Started361178
Completed291036
Not completed7142

Outcome measures

PrimaryNumber of Participants Monitored for Long-term Safety of Valbenazine

Incidence of adverse events and monitoring of vital signs, clinical laboratory values, and electrocardiograms. All AEs were coded into preferred terms according to MedDRA (Medical Dictionary for Regulatory Activities) and classified by system organ class (SOC). Summaries of the incidence of all treatment-emergent AEs, treatment-related AEs, SAEs, and AEs leading to study drug discontinuation were prepared.

Time frame:
60 weeks
Reported as:
Count of participants · Participants
Number of Participants Monitored for Long-term Safety of Valbenazine
ParticipantsValbenazine 40 mgValbenazine 80 mgValbenazine 40/80 mg
Number of Participants Monitored for Long-term Safety of Valbenazine351178
SecondaryNumber of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale

Clinician's perspective of the participant's overall severity of TD symptoms. The CGI-TD-Severity is based on a 7-point scale (range: 1= "Normal, not at all ill" to 7= "Among the most extremely ill patient"). A clinical response was defined as a CGI-TD-S score equal to "1" or "2."

Time frame:
Baseline and Weeks 12, 24, 36, 48, and 60
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale
ParticipantsValbenazine 40 mgValbenazine 80 mgValbenazine 40/80 mg
Baseline2210
Week 1215563
Week 2411564
Week 367442
Week 485292
Week 6022—
SecondaryNumber of Participants With Clinical Response as Assessed by the Patient Satisfaction Questionnaire (PSQ)

Participant's perspective of his/her satisfaction with valbenazine treatment. The PSQ is based on a 5-point scale (range: 1=very satisfied to 5=very dissatisfied). A clinical response was defined as a PSQ score equal to "1" or "2."

Time frame:
Baseline and Weeks 12, 24, 36, 48, and 60
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response as Assessed by the Patient Satisfaction Questionnaire (PSQ)
ParticipantsValbenazine 40 mgValbenazine 80 mgValbenazine 40/80 mg
Baseline351167
Week 12301126
Week 2423926
Week 3617665
Week 4812385
Week 6022—

Adverse events

Collected over Up to 60 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valbenazine 40 mg0/35 (0%)3/35 (8.6%)6/35 (17.1%)
Valbenazine 80 mg3/117 (2.6%)11/117 (9.4%)23/117 (19.7%)
Valbenazine 40/80 mg1/8 (12.5%)2/8 (25%)6/8 (75%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventValbenazine 40 mgValbenazine 80 mgValbenazine 40/80 mg
GoutMetabolism and nutrition disorders0/350/1171/8
Hypertensive heart diseaseCardiac disorders0/350/1171/8
Psychotic disorderPsychiatric disorders1/350/1170/8
DiarrhoeaGastrointestinal disorders1/350/1170/8
Atrial fibrillationCardiac disorders1/350/1170/8
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/351/1170/8
AggressionPsychiatric disorders0/351/1170/8
Non-cardiac chest painGeneral disorders0/351/1170/8
DepressionPsychiatric disorders0/351/1170/8
RhabdomyolysisMusculoskeletal and connective tissue disorders0/351/1170/8
Most frequent other events
Most frequent other events
EventValbenazine 40 mgValbenazine 80 mgValbenazine 40/80 mg
SomnolenceNervous system disorders1/350/1175/8
TremorNervous system disorders0/353/1172/8
CoughRespiratory, thoracic and mediastinal disorders2/353/1171/8
Back painMusculoskeletal and connective tissue disorders2/354/1170/8
Urinary tract infectionInfections and infestations1/356/1170/8
Upper respiratory tract infectionInfections and infestations1/355/1170/8
FallInjury, poisoning and procedural complications1/354/1170/8
HeadacheNervous system disorders1/354/1170/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Valbenazine 40 mgValbenazine 80 mgValbenazine 40/80 mgTotal
Mean57.3 ± 8.957.9 ± 8.859.3 ± 9.057.9 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Valbenazine 40 mgValbenazine 80 mgValbenazine 40/80 mgTotal
Female2254379
Male1363581
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Valbenazine 40 mgValbenazine 80 mgValbenazine 40/80 mgTotal
Hispanic or Latino452157
Not Hispanic or Latino31657103
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Valbenazine 40 mgValbenazine 80 mgValbenazine 40/80 mgTotal
American Indian or Alaska Native0011
Asian0000
Native Hawaiian or Other Pacific Islander0101
Black or African American1430347
White21864111
More than one race0000
Unknown or Not Reported0000
Body Mass Index (BMI) at Baseline
Body Mass Index (BMI) at Baseline(kg/m^2)Valbenazine 40 mgValbenazine 80 mgValbenazine 40/80 mgTotal
Mean29.15 ± 5.5228.54 ± 5.4830.55 ± 5.2928.77 ± 5.46
Primary Psychiatric Diagnosis
Primary Psychiatric Diagnosis(Participants)Valbenazine 40 mgValbenazine 80 mgValbenazine 40/80 mgTotal
Schizophrenia/schizoaffective disorder23756104
Mood disorder1242256
Age at Diagnosis
Age at Diagnosis(years)Valbenazine 40 mgValbenazine 80 mgValbenazine 40/80 mgTotal
Schizophrenia/Schizoaffective Disorder27.1 ± 8.328.7 ± 11.425.3 ± 6.228.2 ± 10.6
Mood Disorder36.0 ± 3.633.9 ± 2.146.0 ± 14.034.7 ± 1.8
Tardive Dyskinesia48.3 ± 11.248.4 ± 9.543.8 ± 13.748.0 ± 10.1
Scales
Scales(units on a scale)Valbenazine 40 mgValbenazine 80 mgValbenazine 40/80 mgTotal
BPRS Score27.3 ± 6.326.1 ± 5.630.5 ± 9.226.6 ± 6.0
CGI-TD-Severity Score3.9 ± 1.13.9 ± 1.34.3 ± 0.73.9 ± 1.2
08

Study locations

27 sites
  • Anaheim, California, United States
  • National City, California, United States
  • Norwalk, California, United States
  • Oakland, California, United States
  • San Bernardino, California, United States
  • San Diego, California, United States
  • Torrance, California, United States
  • Hialeah, Florida, United States
  • North Miami, Florida, United States
  • Orlando, Florida, United States
  • Chicago, Illinois, United States
  • Shreveport, Louisiana, United States
  • Worcester, Massachusetts, United States
  • Cedarhurst, New York, United States
  • Dayton, Ohio, United States
  • Shaker Heights, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Norristown, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Franklin, Tennessee, United States
  • Memphis, Tennessee, United States
  • DeSoto, Texas, United States
  • Fort Worth, Texas, United States
  • Irving, Texas, United States
  • Salt Lake City, Utah, United States
  • Petersburg, Virginia, United States
  • Spokane, Washington, United States
09

References and documents

Publications

  • Lindenmayer JP, Verghese C, Marder SR, Burke J, Jimenez R, Siegert S, Liang GS, O'Brien CF. A long-term, open-label study of valbenazine for tardive dyskinesia. CNS Spectr. 2021 Aug;26(4):345-353. doi: 10.1017/S109285292000108X. Epub 2020 May 18. PubMed 32419679 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Jun 2017, 12 months.

Results were first posted in Dec 2018, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2016
First posted
Apr 13, 2016
StartActual
Jun 13, 2016
Primary completionActual
Jun 30, 2017
CompletionActual
Jun 30, 2017
Results first posted
Dec 19, 2018
Last update
Dec 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02736955
Responsible party
Sponsor
First posted
Apr 13, 2016
Start date
Jun 13, 2016
Primary completion
Jun 30, 2017
Completion
Jun 30, 2017
Results posted
Dec 19, 2018
Last update
Dec 19, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion